Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 3

LUCERNA

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

  • NCT06901531 ↗
  • Recruiting
  • Astellas Pharma Global Development, Inc.
  • 29 commentary sources found
  • Standard

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Commentary we found

Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.

ChannelFound
YouTube13
X threads11
Podcasts5

The trial

ClinicalTrials.gov
Official title
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive
Phase
Phase 3
Status
Recruiting
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab; Pembrolizumab; Capecitabine; Oxaliplatin; Folinic acid (leucovorin or local equivalent); 5-fluorouracil (5-FU); Placebo
Arms
  • Arm A: zolbetuximab in combination with pembrolizumab and chemotherapy · Experimental
  • Arm B: Placebo in combination with pembrolizumab and chemotherapy · Active comparator
Enrollment
500 (estimated)
Primary outcomes
  • Overall Survival (OS)
Sponsor
Astellas Pharma Global Development, Inc.
Start
May 22, 2025
Primary completion
Sep 30, 2028 (estimated)
Results posted
No
Registry record
NCT06901531 · updated Sep 24, 2026